Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0457 in Advanced NSCLC
NCT00290550Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tozasertib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jun 2006; status: terminated.
02
Drugs
tozasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00290550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290550.